Bohr Pharmaceutical: BGM0504 tablets for weight loss showed positive results in Phase I clinical trial.

Borui Pharmaceuticals announced that their self-developed BGM0504 tablets have achieved positive results in Phase I clinical trials for the treatment of overweight/obese adults in China and the United States. In the Chinese Phase I clinical trial of BGM0504 tablets, a total of 75 participants were enrolled, all completing the trial without any serious adverse events, and achieving an average weight reduction of 1.04% to 5.56%. In the U.S. Phase I clinical study, a total of 80 participants were enrolled, with a dose-dependent weight loss effect observed, ranging from 2.7% to 8.2%. Based on good safety/tolerance, preliminary pharmacokinetics, and efficacy data, support for BGM0504 as a potential once-daily oral treatment for overweight or obesity continues to lead to subsequent Phase II clinical studies.